Deal notes
The $3.3 million is cash raised by exercising 854,002 existing warrants at $3.866. Four original cohorts had strikes of $6.38–$7.62; the filings do not allocate the exercises among those cohorts. Two new investor warrant series total 1,708,004 shares at $3.616, with different expiry terms. Agent warrants are separate compensation.
Original source ↗Transaction overview
01SeaStar Medical Holding Corp completed a $3.3M warrant exercise / inducement. H.C. Wainwright acted as exclusive placement agent for the financing.
- Financing type
- Warrant Exercise / Inducement
- Announcement date
- Oct 5, 2026
- Agreement date
- Oct 2, 2026
- Pricing date
- —
- Closing date
- Oct 5, 2026
- Filing date
- Oct 5, 2026
- Status
- Closed
- Market cap before announcement
- $19.2M
- Prior closing price
- $4.69
- Raise as % of market cap
- 17.2%
Market data · FMP
- Historical market cap
- $19,155,287
- Market date
- Oct 2, 2026
- Closing price
- $4.69
- Latest reported shares outstanding
- 2,837,944
- Latest reported float shares
- 2,818,545
- Share-data date
- Oct 8, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 9, 2026.
Financial Modeling Prep ↗Financing terms
02Warrant exercise / inducement
- Warrants exercised
- 854,002
- Original exercise price
- Varies by original cohort
- Exercise price paid
- $3.866
- Cash proceeds
- $3.3M
Security structure
- Price / security basis
- Common shares
- Units offered
- —
- Preferred class
- Not applicable
- Preferred shares offered
- —
Original warrant cohorts
June 2025 — expires June 2030
- Originally issued
- Jun 23, 2025
- Original exercise price
- $6.50
- Exercised from this cohort
- —
June 2025 — expires December 2026
- Originally issued
- Jun 23, 2025
- Original exercise price
- $6.50
- Exercised from this cohort
- —
July 2025 — expires August 2030
- Originally issued
- Jul 11, 2025
- Original exercise price
- $6.38
- Exercised from this cohort
- —
August 2025 — expires August 2030
- Originally issued
- Aug 1, 2025
- Original exercise price
- $7.62
- Exercised from this cohort
- —
The filings disclose 854,002 exercises in aggregate but do not allocate that count among the four original warrant cohorts. Original strikes and issuance dates are retained separately.
New Series A warrants
- Warrant shares
- 854,002
- Cash exercise price
- $3.616
- Term
- Five years from effectiveness of the resale registration statement; immediately exercisable.
- Initial exercisability
- —
- Beneficial ownership limits
- —
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
New Series B warrants
- Warrant shares
- 854,002
- Cash exercise price
- $3.616
- Term
- Eighteen months from effectiveness of the resale registration statement; immediately exercisable.
- Initial exercisability
- —
- Beneficial ownership limits
- —
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
Placement agent warrants
- Warrant shares
- 59,780
- Cash exercise price
- $4.8325
- Term
- Five years from effectiveness of the resale registration statement; immediately exercisable.
- Initial exercisability
- —
- Beneficial ownership limits
- —
Compensation warrants are excluded from investor warrant coverage.
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
Fees & transaction economics
03- Placement agent / underwriting fee
- 7%
- Agent fee amount
- $231,000
- Management fee
- 1%
- Other offering expenses (estimated)
- $90,950
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
7% cash placement fee plus 1% management fee; $75,000 non-accountable expenses and $15,950 clearing fee. Agent warrants are separate compensation.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
5
The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of 59,780 shares of Common Stock (the “PA Warrants” and the shares of Common Stock issuable upon exercise of the PA Warrants, the “PA Warrant Shares”). The PA Warrants are immediately exercisable, have a term of five years from the effective date of the Resale Registration Statement, and have an exercise price of $4.8325 per share.Original source ↗
Common shares
On October 2, 2026, SeaStar Medical Holding Corporation (the “Company”) entered into letter agreements (the “Letter Agreements”) with holders (the “Holders”) of certain of its issued and outstanding common stock purchase warrants (the “Prior Warrants”) to purchase an aggregate of 854,002 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), pursuant to which the Holders exercised their Prior Warrants for cash at a reduced exercise price equal to $3.866 per share (the “Reduced Exercise Price”).Original source ↗
The filings disclose 854,002 exercises in aggregate but do not allocate that count among the four original warrant cohorts. Original strikes and issuance dates are retained separately.
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
Warrant Exercise / Inducement
On October 2, 2026, SeaStar Medical Holding Corporation (the “Company”) entered into letter agreements (the “Letter Agreements”) with holders (the “Holders”) of certain of its issued and outstanding common stock purchase warrants (the “Prior Warrants”) to purchase an aggregate of 854,002 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), pursuant to which the Holders exercised their Prior Warrants for cash at a reduced exercise price equal to $3.866 per share (the “Reduced Exercise Price”).Original source ↗
Closed
The gross proceeds to the Company from the exercise of the Prior Warrants were approximately $3.3 million prior to deducting placement agent fees and offering expenses. The closing of the offering occurred on October 5, 2026.Original source ↗
announcement
DENVER, CO., October 5, 2026 – SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026Original source ↗
2026-10-05
DENVER, CO., October 5, 2026 – SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026Original source ↗
2026-10-02
On October 2, 2026, SeaStar Medical Holding Corporation (the “Company”) entered into letter agreements (the “Letter Agreements”) with holders (the “Holders”) of certain of its issued and outstanding common stock purchase warrants (the “Prior Warrants”) to purchase an aggregate of 854,002 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), pursuant to which the Holders exercised their Prior Warrants for cash at a reduced exercise price equal to $3.866 per share (the “Reduced Exercise Price”).Original source ↗
2026-10-05
The gross proceeds to the Company from the exercise of the Prior Warrants were approximately $3.3 million prior to deducting placement agent fees and offering expenses. The closing of the offering occurred on October 5, 2026.Original source ↗
3300000
The gross proceeds to the Company from the exercise of the Prior Warrants were approximately $3.3 million prior to deducting placement agent fees and offering expenses. The closing of the offering occurred on October 5, 2026.Original source ↗
854002
On October 2, 2026, SeaStar Medical Holding Corporation (the “Company”) entered into letter agreements (the “Letter Agreements”) with holders (the “Holders”) of certain of its issued and outstanding common stock purchase warrants (the “Prior Warrants”) to purchase an aggregate of 854,002 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), pursuant to which the Holders exercised their Prior Warrants for cash at a reduced exercise price equal to $3.866 per share (the “Reduced Exercise Price”).Original source ↗
7
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the offering pursuant to an engagement agreement between the Company and Wainwright dated as of September 24, 2026. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering, $75,000 of non-accountable expenses and $15,950 for its clearing fee.Original source ↗
1
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the offering pursuant to an engagement agreement between the Company and Wainwright dated as of September 24, 2026. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering, $75,000 of non-accountable expenses and $15,950 for its clearing fee.Original source ↗
90950
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the offering pursuant to an engagement agreement between the Company and Wainwright dated as of September 24, 2026. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering, $75,000 of non-accountable expenses and $15,950 for its clearing fee.Original source ↗
7% cash placement fee plus 1% management fee; $75,000 non-accountable expenses and $15,950 clearing fee. Agent warrants are separate compensation.
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the offering pursuant to an engagement agreement between the Company and Wainwright dated as of September 24, 2026. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering, $75,000 of non-accountable expenses and $15,950 for its clearing fee.Original source ↗
854002
On October 2, 2026, SeaStar Medical Holding Corporation (the “Company”) entered into letter agreements (the “Letter Agreements”) with holders (the “Holders”) of certain of its issued and outstanding common stock purchase warrants (the “Prior Warrants”) to purchase an aggregate of 854,002 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), pursuant to which the Holders exercised their Prior Warrants for cash at a reduced exercise price equal to $3.866 per share (the “Reduced Exercise Price”).Original source ↗
3.866
On October 2, 2026, SeaStar Medical Holding Corporation (the “Company”) entered into letter agreements (the “Letter Agreements”) with holders (the “Holders”) of certain of its issued and outstanding common stock purchase warrants (the “Prior Warrants”) to purchase an aggregate of 854,002 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), pursuant to which the Holders exercised their Prior Warrants for cash at a reduced exercise price equal to $3.866 per share (the “Reduced Exercise Price”).Original source ↗
FMP reported market cap; as of 2026-10-02.
{"provider":"FMP","policy":"fmp-primary-v1","symbol":"ICU","marketCap":19155287,"closingPrice":4.69,"asOf":"2026-10-02","retrievedAt":"2026-10-09T20:08:53.236781+00:00","outstandingShares":2837944,"floatShares":2818545,"sharesAsOf":"2026-10-08","sharesBasis":"latest_provider_snapshot","marketCapSource":"https://site.financialmodelingprep.com/developer/docs","priceSource":"https://site.financialmodelingprep.com/developer/docs","sharesSource":"https://site.financialmodelingprep.com/developer/docs"}Original source ↗
854002
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
Five years from effectiveness of the resale registration statement; immediately exercisable.
The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of 59,780 shares of Common Stock (the “PA Warrants” and the shares of Common Stock issuable upon exercise of the PA Warrants, the “PA Warrant Shares”). The PA Warrants are immediately exercisable, have a term of five years from the effective date of the Resale Registration Statement, and have an exercise price of $4.8325 per share.Original source ↗
3.616
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
5
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
Five years from effectiveness of the resale registration statement; immediately exercisable.
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
854002
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
3.616
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
1.5
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
Eighteen months from effectiveness of the resale registration statement; immediately exercisable.
In addition, the Holders received new unregistered Series A common stock purchase warrants (the “Series A Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series A Warrant Shares”) and new unregistered Series B common stock purchase warrants (the “Series B Warrants” and, together with the Series A Warrants, the “New Warrants”) exercisable for up to an aggregate of 854,002 shares of Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “New Warrant Shares”). The New Warrants are immediately exercisable and have an exercise price of $3.616 per share. The Series A Warrants have a term of exercise equal to five years from the effective date of the Resale Registration Statement (as defined below), and the Series B Warrants have a term of exercise equal to 18 months from the effective date of the Resale Registration Statement.Original source ↗
59780
The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of 59,780 shares of Common Stock (the “PA Warrants” and the shares of Common Stock issuable upon exercise of the PA Warrants, the “PA Warrant Shares”). The PA Warrants are immediately exercisable, have a term of five years from the effective date of the Resale Registration Statement, and have an exercise price of $4.8325 per share.Original source ↗
4.8325
The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of 59,780 shares of Common Stock (the “PA Warrants” and the shares of Common Stock issuable upon exercise of the PA Warrants, the “PA Warrant Shares”). The PA Warrants are immediately exercisable, have a term of five years from the effective date of the Resale Registration Statement, and have an exercise price of $4.8325 per share.Original source ↗
2025-06-23
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
6.5
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
2025-06-23
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
6.5
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
2025-07-11
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
6.38
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
2025-08-01
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗
7.62
6 Exhibit A ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of June 23, 2030. ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on June 23, 2025, at an exercise price of $6.50 per share and an expiration date of December 23, 2026 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on July 11, 2025, at an exercise price of $6.38 per share and an expiration date of August 12, 2030 ● Common Stock Purchase Warrants to purchase shares of Common Stock issued on August 1, 2025, at an exercise price of $7.62 per share and an expiration date of August 12, 2030 Collectively, the “ Existing Warrants ”Original source ↗